Advanced

Neural tissue xenografting

Larsson, L C LU and Widner, H LU (2000) In Scandinavian Journal of Immunology 52(3). p.56-249
Abstract

Neural transplantation may become an important treatment alternative for focal brain disorders. To date, the most successful grafts have been obtained in patients with Parkinson's disease. Completely normalized dopamine production and reduction of Parkinsonian symptoms have been demonstrated 10 years after grafting. However, the allogeneic donor tissue has to be obtained from induced abortions, and there are logistical difficulties, risks of infection, and ethical constraints limiting a wider clinical use. Xenografting is an alternative that could bridge these limitations if immunological rejection could be prevented. Pig embryonic neural tissue has been grafted to patients with Parkinson's disease, but no functional benefits have... (More)

Neural transplantation may become an important treatment alternative for focal brain disorders. To date, the most successful grafts have been obtained in patients with Parkinson's disease. Completely normalized dopamine production and reduction of Parkinsonian symptoms have been demonstrated 10 years after grafting. However, the allogeneic donor tissue has to be obtained from induced abortions, and there are logistical difficulties, risks of infection, and ethical constraints limiting a wider clinical use. Xenografting is an alternative that could bridge these limitations if immunological rejection could be prevented. Pig embryonic neural tissue has been grafted to patients with Parkinson's disease, but no functional benefits have clinically been proven so far. The immune reactions to neural xenografts were incompletely characterized at the time of these early clinical trials, and it is likely that the treatments used were insufficient and that the grafts were rejected. In this article we will review new experiments addressing the immune responses against porcine neural tissue grafted to the adult brain, including the role of antibodies, complement, natural killer (NK) cells, lymphocytes, as well as the effects of immunosuppressive drugs and donor tissue modifications.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Animals, Antibodies, Heterophile, Antibody-Dependent Cell Cytotoxicity, Blood-Brain Barrier, Brain Tissue Transplantation, Complement System Proteins, Ethics, Medical, Fetal Tissue Transplantation, Graft Enhancement, Immunologic, Graft Rejection, Humans, Immunosuppressive Agents, Killer Cells, Natural, Lymphocyte Subsets, Nerve Tissue, Parkinson Disease, Phagocytes, Rodentia, Safety, Swine, Transplantation, Heterologous, Zoonoses, Journal Article, Research Support, Non-U.S. Gov't, Review
in
Scandinavian Journal of Immunology
volume
52
issue
3
pages
8 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:0033855844
ISSN
0300-9475
DOI
10.1046/j.1365-3083.2000.00796.x
language
English
LU publication?
yes
id
d3d71687-689e-4552-9f78-f236082a1367
date added to LUP
2017-04-19 18:19:22
date last changed
2017-09-24 05:09:48
@article{d3d71687-689e-4552-9f78-f236082a1367,
  abstract     = {<p>Neural transplantation may become an important treatment alternative for focal brain disorders. To date, the most successful grafts have been obtained in patients with Parkinson's disease. Completely normalized dopamine production and reduction of Parkinsonian symptoms have been demonstrated 10 years after grafting. However, the allogeneic donor tissue has to be obtained from induced abortions, and there are logistical difficulties, risks of infection, and ethical constraints limiting a wider clinical use. Xenografting is an alternative that could bridge these limitations if immunological rejection could be prevented. Pig embryonic neural tissue has been grafted to patients with Parkinson's disease, but no functional benefits have clinically been proven so far. The immune reactions to neural xenografts were incompletely characterized at the time of these early clinical trials, and it is likely that the treatments used were insufficient and that the grafts were rejected. In this article we will review new experiments addressing the immune responses against porcine neural tissue grafted to the adult brain, including the role of antibodies, complement, natural killer (NK) cells, lymphocytes, as well as the effects of immunosuppressive drugs and donor tissue modifications.</p>},
  author       = {Larsson, L C and Widner, H},
  issn         = {0300-9475},
  keyword      = {Adult,Animals,Antibodies, Heterophile,Antibody-Dependent Cell Cytotoxicity,Blood-Brain Barrier,Brain Tissue Transplantation,Complement System Proteins,Ethics, Medical,Fetal Tissue Transplantation,Graft Enhancement, Immunologic,Graft Rejection,Humans,Immunosuppressive Agents,Killer Cells, Natural,Lymphocyte Subsets,Nerve Tissue,Parkinson Disease,Phagocytes,Rodentia,Safety,Swine,Transplantation, Heterologous,Zoonoses,Journal Article,Research Support, Non-U.S. Gov't,Review},
  language     = {eng},
  number       = {3},
  pages        = {56--249},
  publisher    = {Wiley-Blackwell},
  series       = {Scandinavian Journal of Immunology},
  title        = {Neural tissue xenografting},
  url          = {http://dx.doi.org/10.1046/j.1365-3083.2000.00796.x},
  volume       = {52},
  year         = {2000},
}